Woodline Partners’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Woodline Partners’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-205,108	Closed	-$20.9M	–	790
2023 Q2	$20.9M	Buy	+205,108	New	+$19.4M	0.25%	116
2021 Q2	–	Sell	-5,121	Closed	-$511K	–	663
2021 Q1	$511K	Sell	5,121 -67,976	-93%	-$7.93M	0.01%	390
2020 Q4	$9.04M	Buy	+73,097	New	+$9.61M	0.24%	121

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Woodline Partners's RETA Position: Q3 2023 in Review

Woodline Partners sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 205,108 shares — an estimated $20.9M sold.

Woodline Partners first reported a position in RETA in Q4 2020 and held it in 3 quarters. The position peaked at $20.9M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Woodline Partners reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Woodline Partners sold 205,108 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $20.9M.
Woodline Partners first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2020 and held it in 3 quarters.
Woodline Partners's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $20.9M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Woodline Partners's 13F filing for Q3 2023, filed 14 Nov 2023.